Ocata Therapeutics, Inc. (NASDAQ:OCAT) was established in 2007 and is headquartered in Marlborough, Massachusetts. It has 37 full-time employees. It is a clinical-stage biotechnology company engaged in the development, research and sales of ophthalmic regenerative therapies in the United States.
Update: In May 2016, Japanese pharmaceutical company Astellas Pharma acquired Ocata Therapeutics and the latter was delisted.
Ocata Therapeutics (OCAT):
Ocata Therapeutics was founded in 2007 in MA in the United States. Its predecessor was Advanced Cell Technology Inc., which was changed to its current name in November 2014. As of February 11, 2015, Ocata has 58 patents and 180 patents pending, which constitute the company’s strong intellectual property portfolio.
Ocata Therapeutics focuses on the development of ophthalmic regenerative therapy and is conducting various clinical trials for the treatment of Stargardt’s macular degeneration (Stargardt’s macular degeneration), age-related dry macular degeneration and myopic macular degeneration, as well as various other eye diseases Preclinical trials of drugs; In addition, Ocata Therapeutics also has products & therapies in preclinical trials for autoimmune diseases, inflammatory and wound healing related diseases.
Ocata’s strong intellectual property rights & patent protection mainly include: pluripotent stem cell platforms (such as human embryonic stem cells and induced pluripotent stem cells), cell therapy research (such as ophthalmological programs, including macular degeneration, photosensitive progenitors, and retinal ganglia) Cell progenitor cells and corneal endothelial programs, etc.), mesenchymal stem cell patents, neuroprotective biology, platelet programs, etc.
Ocata Therapeutics (OCAT) investment: